U.S. markets closed

DaVita Inc. (DVA)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
118.75-0.89 (-0.74%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close119.64
Bid118.95 x 1100
Ask119.02 x 800
Day's Range117.65 - 119.84
52 Week Range62.20 - 125.28
Avg. Volume782,180
Market Cap13.3B
Beta (5Y Monthly)1.31
PE Ratio (TTM)17.78
EPS (TTM)6.68
Earnings DateFeb 08, 2021 - Feb 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est116.56
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Near Fair Value
2% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • NextGen's (NXGN) Platform Gets Adopted by FPA Women's Health

    NextGen's (NXGN) Platform Gets Adopted by FPA Women's Health

    FPA Women's Health utilizes NextGen's (NXGN) Virtual Visits, which are integral to the company's Patient Experience Platform

  • Benzinga

    A Look Into DaVita's Price Over Earnings

    In the current market session, DaVita Inc. (NYSE: DVA) is trading at $116.15, after a 0.29% decrease. However, over the past month, the stock spiked by 5.08%, and in the past year, by 53.57%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The stock is currently under from its 52 week high by 2.13%. The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E indicates that shareholders do not expect the stock to perform better in the future, and that the company is probably undervalued. It shows that shareholders are less than willing to pay a high share price, because they do not expect the company to exhibit growth, in terms of future earnings. View more earnings on DVADepending on the particular phase of a business cycle, some industries will perform better than others. DaVita Inc. has a lower P/E than the aggregate P/E of 55.99 of the Health Care Providers & Services industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. P/E ratio is not always a great indicator of the company's performance. Depending on the earnings makeup of a company, investors can become unable to attain key insights from trailing earnings.See more from Benzinga * Click here for options trades from Benzinga * Stocks That Hit 52-Week Highs On Monday * Stocks That Hit 52-Week Highs On Wednesday(C) 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Early Risk Identification at Core of Innovative Kidney Care Partnership Between Renalytix, DaVita

    Early Risk Identification at Core of Innovative Kidney Care Partnership Between Renalytix, DaVita

    First-of-its-kind program combines early risk assessment of kidney decline and comprehensive care management to help slow kidney disease progression, improve care coordination and reduce costsNEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Kidney care innovators Renalytix AI (NASDAQ:RNLX, LSE:RENX) and DaVita (NYSE: DVA) are partnering on a program aimed at slowing disease progression and improving health outcomes for the nation’s estimated 37 million adults with chronic kidney disease (CKD). The program is expected to improve patient outcomes and provide meaningful cost reductions for health care providers and payors by enabling earlier intervention for patients with early-stage kidney disease (stages 1, 2 and 3) through actionable risk assessments and end-to-end care management. The collaboration is expected to launch in three major markets this year. As the program expands, DaVita and RenalytixAI intend to pursue risk-sharing arrangements with health care providers and payors to drive kidney disease patient care innovation, cost efficiencies and improve quality of life.“Almost 50% of people whose kidneys fail find out after it is too late, and we are on a mission to change that,” said Javier Rodriguez, Chief Executive Officer for DaVita. “Our partnership with RenalytixAI could allow us to help slow disease progression for the millions of people living with kidney disease.”“This is the first clinical-grade program that delivers advanced early-stage prognosis and risk stratification, combined with actionable care management right to the primary care level where the majority of kidney disease patients are being seen,” said James McCullough, Renalytix AI Chief Executive Officer. “Making fundamental change in kidney disease health economics and outcomes must begin with providing a clear, actionable understanding of disease progression risk.”The program utilizes the KidneyIntelX in vitro diagnostic platform from RenalytixAI, which uses a machine learning algorithm to assess a combination of biomarkers from a simple blood draw with features from the electronic health record to generate a patient-specific risk score. The initial version of the KidneyIntelX risk score identifies Type 2 diabetic patients with early-stage CKD as low-, intermediate- or high-risk for progressive decline in kidney function or kidney failure. The integrated program may also help reduce kidney disease misclassification, which leaves some higher-risk patients without recommended treatment. The expected outcome of the collaboration will also be used to expand indicated use claims for KidneyIntelX.After risk stratification, program patients identified as intermediate- and high-risk will receive care management support through DaVita’s integrated kidney care program, for which Renalytix will compensate DaVita in lieu of providing those services itself. DaVita’s integrated kidney care program is comprised of a coordinated care team, practical digital health tools, award-winning patient education and other offerings. Focused on the patient experience, these services are designed to empower patients to be active in their care, delay disease progression, improve outcomes and lower costs. DaVita’s team also closely collaborates with the treating nephrologist, who leads the care team, to create a seamless care experience.For patients whose kidney disease does progress, earlier intervention can provide the patient and treating nephrologist more time to make an informed decision about the treatment option that is best for them, including pre-emptive transplantation, home dialysis or in-center dialysis. For those patients who choose to begin dialysis, the extra time increases their chance for an out-patient dialysis starts, which can help them to avoid starting dialysis with a costly hospitalization.Forward-Looking Statements Certain statements in this press release are forward-looking statements that are subject to risks and uncertainties. These forward-looking statements include, for example, statements related to the potential benefits of the partnership between RenalytixAI and DaVita to patients, health care providers and payors. Forward-looking statements in this press release are based on management's current expectations. Various important factors could cause actual results to differ materially from these forward-looking statements, including the risks identified in the U.S. Securities and Exchange Commission filings of DaVita and RenalytixAI. Each of RenalytixAI and DaVita disclaims any obligation to update any forward-looking statement contained in this press release, except as may be otherwise required by law.About RenalytixAI RenalytixAI (NASDAQ:RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX.com (visit www.kidneyintelx.com) which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit www.renalytixai.com.About DaVita DaVita (NYSE: DVA) is a health care provider focused on transforming care delivery to improve quality of life for patients globally. The company is one of the largest providers of kidney care services in the U.S. and has been a leader in clinical quality and innovation for more than 20 years. Through DaVita Kidney Care, the company treats patients with chronic kidney failure and end stage kidney disease. DaVita is committed to bold, patient-centric care models, implementing the latest technologies and moving toward integrated care offerings for all. Through these efforts, DaVita has also become the largest provider of home dialysis in the country. As of September 30, 2020, DaVita served 205,300 patients at 2,809 outpatient dialysis centers in the United States. The company also operated 291 outpatient dialysis centers in nine countries worldwide. DaVita has reduced hospitalizations, improved mortality, and worked collaboratively to propel the kidney care industry to adopt an equitable and high-quality standard of care for all patients, everywhere. To learn more, visit DaVita.com/About.Media Contacts:United States: Jennifer Moritz Zer0 to 5ive for RenalytixAI (917) 748-4006 jmoritz@0to5.com Outside of the United States: Walbrook PR Limited Paul McManus / Lianne Cawthorne Tel: 020 7933 8780 or renalytix@walbrookpr.com Mob: 07980 541 893 / 07584 391 303